PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for February 23, 2007 Add to my Yahoo! Subscribe to this News Feed Subscribe to this News Feed   Subscribe to this Podcast Feed PodcastiTunes
 

Colorado Bioscience Association Showcases the State's Most Promising Technologies

Colorado research institutions have begun reaping the rewards of legislation allocating state funds for bioscience research. HB 1360, sponsored by Representative Jim Reisberg (D-Greeley) and Senator Ron Tupa (D-Boulder), was signed into law by Governor Bill Owens last summer. $2 million in state funds was awarded to 27 bioscience proof of concept projects at six Colorado universities and research institutions. Initial reports are expected by the end of 2007.

Denver, CO (PRWEB) February 23, 2007 -- Colorado research institutions have begun reaping the rewards of legislation allocating state funds for bioscience research. The announcement is made by Denise Brown, Executive Director of Colorado Bioscience Association (CBSA), who says the grants stem from legislation initiated by CBSA in 2006.

HB 1360, sponsored by Representative Jim Reisberg (D-Greeley) and Senator Ron Tupa (D-Boulder), was signed into law by Governor Bill Owens last summer. The Colorado Office of Economic Development and International Trade (OEDIT), in turn, administered the grant process.

"The legislation appropriated $2 million for bioscience proof of concept work on technologies showing promise for commercialization," explains Rep. Reisberg. "Research institutions are eligible for up to $150,000 per grant. However, they must provide a one-to-one match for each funded project. We expect these projects will result in five to 10 new companies for our state in the years ahead."

The $2 million in state funds was awarded to the following 27 bioscience proof of concept projects at six Colorado universities and research institutions:

UNIVERSITY OF COLORADO

 
  • New treatment for ineffectively treated schizophrenia patients

  • Suppression of irradiation -induced salivary gland dysfunctionby IGF - 1

  • Device for laser fusion of septal tissue

  • Validation of SARS coronavirus antibody technology of influenza virus

  • Hydroquinone ansamysin prodrugs as novel anticancer Hsp90 inhibitors

  • Infusion of alpha-1-antitrypsin (ATT) to suppress Human Immunodeficiency Virus Type 1 (HIV) replication in patients

  • In vivo analysis of a cardiac and skeletal muscle stem cell activator

  • Biomarker Enabled Development of PARP Inhibitors for Cancer Therapy

  • A Novel biology targeted agent for the treatment of non-small cell lung cancer

  • Redox-Initiated Radical Chain Polymerization for the Detection and amplification of biological recognition events

  • Moving Bryostatin-1 from the lab to the clinic for the treatment of pulmonary hypertension

  • New targeted drug for the treatment of lung cancer

  • Protein biomarkers to differentially diagnose follicular thyroid carcinoma and follicular thyroid adenoma


  • COLORADO STATE UNIVERSITY

  • Coherence-modulated molecular specific nonlinear optical microscopy

  • Evaluation of a dynamic external cardiac device for the treatment of functional mitral valve regurgitation

  • A Development proposal for and instrumented cervical intervertebral disc space distractor

  • Evaluation of lymphactic drainage and uptake following intracavitary chemotherapy administration for mammary carcinoma

  • Phytodetectors: plants designed to be highly specific detectors of environmental pollutants


  • NATIONAL JEWISH MEDICAL AND RESEARCH CENTER

  • Use of soluble gamma/delta t-cell receptors in reducing inflammatory damage

  • Development of Novel Therapies to Treat Chronic Lung Disease

  • Heat shock proteins modify lung allergic inflammatory responses

  • Inhaled and t-cell-receptor antibodies for the treatment of airway hyper-responsiveness and inflammation

  • A method for the Prevention and treatment of pseudomonas biofilm infections


  • BELLE BONFILS BLOOD CENTER

  • Transfusion related acute lung injury identification test kit (neutrophil priming activity)


  • UNIVERSITY OF DENVER

  • Gait monitor for fall prevention business plan

  • Encoding and screening of solution phase combinatorial libraries for drug candidates


  • UNIVERSITY OF NORTHERN COLORADO

  • New compounds from snake venoms: a proteomics approach toward the development of drugs from toxins

Initial reports on these projects should begin by the end of 2007. To read a full summary of each project, click to the following pdf: http://301url.com/HB1360Summaries

About the Colorado Office of Economic Development and International Trade

OEDIT works with companies starting, expanding, or relocating in Colorado. OEDIT offers a wide range of services to assist new and existing business of every size. Visit http://www.AdvanceColorado.com

About Colorado BioScience Association

CBSA is a not-for-profit corporation providing services and support for Colorado's growing biosciences industry. With more than 300 members, CBSA actively works to promote the growth of the industry by working for a better business environment, growing the state's biotech workforce, fighting for policies that support a strong bioscience industry in the state and speaking with a single voice on behalf of the industry. For more information, visit http://www.cobioscience.com


Contacts:

Denise Brown, Executive Director, Colorado BioScience Association http://www.cobioscience.com -- 303.592.4073

Maggie Chamberlin Holben, APR, Absolutely Public Relations http://www.absolutelypr.com -- 303.984.9801

###

Other Releases by this Member
OPTIONS
Printer Friendly Printer Friendly Version
Email Email this story to a colleague
CONTACT INFORMATION
MAGGIE HOLBEN
Colorado Bioscience Association
303-984-9801
Email us Here
ATTACHED FILES

About Colorado Bioscience Association
CBSA is a not-for-profit corporation providing services and support for Colorado's growing biosciences industry. With more than 300 members, CBSA actively works to promote the growth of the industry by working for a better business environment, growing the state's biotech workforce, fighting for policies that support a strong bioscience industry in the state and speaking with a single voice on behalf of the industry.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.